100 years of ibogaine: neurochemical and pharmacological actions of a putative anti-addictive drug.
Pharmacological Reviews June 1, 1995 P Popik, R T Layer, P Skolnick 185 citations
No Summary
4 papers in the library · 325 citations · publishing 1991-1996
Pharmacological Reviews June 1, 1995 P Popik, R T Layer, P Skolnick 185 citations
No Summary
Psychopharmacology May 1, 1994 P Popik, R T Layer, P Skolnick 92 citations
Ibogaine, a potential treatment for addiction to opiates, stimulants, and alcohol, acts as a competitive inhibitor of NMDA receptor coupled cation channels, binding to the same site as MK-801. This suggests that ibogaine's ability to reduce drug-seeking behavior in humans may stem from blocking these channels, similar to how MK-801 prevents tolerance to morphine and alcohol and reduces sensitization to stimulants in animal studies.
European journal of pharmacology August 8, 1996 R T Layer, P Skolnick, C M Bertha et al. 48 citations
Ibogaine, a psychoactive alkaloid, is more potent than its analogs at blocking NMDA receptors, a brain target linked to addiction. In lab tests, ibogaine inhibited [3H]MK-801 binding to NMDA receptors most strongly (Ki ≈ 1.2 µM), while similar compounds like O-desmethylibogaine were less potent (Ki ≈ 5.5 µM) and O-t-butyl-O-desmethylibogaine much weaker (Ki ≈ 179 µM). In morphine-dependent mice, only ibogaine reduced withdrawal jumping triggered by naloxone, suggesting its anti-addictive effects stem from NMDA receptor antagonism.
Psychopharmacology January 1, 1991 G E Evoniuk, R P Hertzman, P Skolnick
A simple method detects behavioral effects of dissociative anesthetics like phencyclidine (PCP) and dizolcipine in mice. These drugs, which bind to NMDA-coupled cation channels, caused a dose-related increase in the percentage of mice falling from a circular arena on a 60 cm platform. Other compounds, including competitive NMDA antagonists and sigma-receptor ligands with low PCP receptor affinity, did not produce this behavior. Pretreatment with glycine reduced falls caused by a maximally effective dose of dizolcipine in a dose-dependent manner. This procedure may aid rapid detection of dissociative anesthetics and evaluation of PCP antagonists.